Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dalpiciclib + chidamide + letrozole single-arm study in HR-positive/HER2-negative breast cancer
ChiCTR2400081280Phase 4Not yet recruiting
- Sponsor
- Anyang Cancer Hospital
- Start
- Feb 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of dalpiciclib, tucidinostat and letrozole in breast cancer, sponsored by Anyang Cancer Hospital. Primary endpoints: Pathologic complete response and Residual cancer burden 0-I. Planned start Feb 2024; status: not yet recruiting.
02
Drugs
dalpiciclibtucidinostatletrozole
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2400081280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400081280.